Get Premium to unlock powerful stock data

Ikarian Capital, LLC Buys Bicycle Therapeutics PLC, Apellis Pharmaceuticals Inc, Inhibrx Inc, Sells Biogen Inc, CRISPR Therapeutics AG, Alector Inc

Author's Avatar
insider
Nov 15, 2021
Article's Main Image
Investment company Ikarian Capital, LLC (Current Portfolio) buys Bicycle Therapeutics PLC, Apellis Pharmaceuticals Inc, Inhibrx Inc, Immatics NV, Ayala Pharmaceuticals Inc, sells Biogen Inc, CRISPR Therapeutics AG, Alector Inc, Relmada Therapeutics Inc, Annovis Bio Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Ikarian Capital, LLC. As of 2021Q3, Ikarian Capital, LLC owns 209 stocks with a total value of $1.4 billion. These are the details of the buys and sells.

For the details of Ikarian Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/ikarian+capital%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Ikarian Capital, LLC
  1. S&P 500 ETF TRUST ETF (SPY) - 300,000 shares, 9.07% of the total portfolio.
  2. SPDR Biotech ETF (XBI) - 650,000 shares, 5.75% of the total portfolio.
  3. Biogen Inc (BIIB) - 167,500 shares, 3.34% of the total portfolio.
  4. Reata Pharmaceuticals Inc (RETA) - 471,400 shares, 3.34% of the total portfolio.
  5. Horizon Therapeutics PLC (HZNP) - 421,900 shares, 3.25% of the total portfolio.
New Purchase: Bicycle Therapeutics PLC (BCYC)

Ikarian Capital, LLC initiated holding in Bicycle Therapeutics PLC. The purchase prices were between $27.95 and $44.24, with an estimated average price of $35.01. The stock is now traded at around $60.700000. The impact to a portfolio due to this purchase was 1.54%. The holding were 526,500 shares as of 2021-09-30.

New Purchase: Apellis Pharmaceuticals Inc (APLS)

Ikarian Capital, LLC initiated holding in Apellis Pharmaceuticals Inc. The purchase prices were between $31.4 and $69.84, with an estimated average price of $56.51. The stock is now traded at around $42.200000. The impact to a portfolio due to this purchase was 0.81%. The holding were 347,545 shares as of 2021-09-30.

New Purchase: Zentalis Pharmaceuticals Inc (ZNTL)

Ikarian Capital, LLC initiated holding in Zentalis Pharmaceuticals Inc. The purchase prices were between $46.83 and $73.5, with an estimated average price of $57.7. The stock is now traded at around $74.970000. The impact to a portfolio due to this purchase was 0.43%. The holding were 92,344 shares as of 2021-09-30.

New Purchase: Ayala Pharmaceuticals Inc (AYLA)

Ikarian Capital, LLC initiated holding in Ayala Pharmaceuticals Inc. The purchase prices were between $8.13 and $14.09, with an estimated average price of $11.98. The stock is now traded at around $11.540000. The impact to a portfolio due to this purchase was 0.43%. The holding were 538,939 shares as of 2021-09-30.

New Purchase: WAVE Life Sciences Ltd (WVE)

Ikarian Capital, LLC initiated holding in WAVE Life Sciences Ltd. The purchase prices were between $4.89 and $7.12, with an estimated average price of $6.07. The stock is now traded at around $4.590000. The impact to a portfolio due to this purchase was 0.34%. The holding were 993,481 shares as of 2021-09-30.

New Purchase: Seres Therapeutics Inc (MCRB)

Ikarian Capital, LLC initiated holding in Seres Therapeutics Inc. The purchase prices were between $5.46 and $22.6, with an estimated average price of $9.91. The stock is now traded at around $7.890000. The impact to a portfolio due to this purchase was 0.3%. The holding were 606,554 shares as of 2021-09-30.

Added: Inhibrx Inc (INBX)

Ikarian Capital, LLC added to a holding in Inhibrx Inc by 3489.03%. The purchase prices were between $25.18 and $37.81, with an estimated average price of $30.45. The stock is now traded at around $43.715000. The impact to a portfolio due to this purchase was 0.66%. The holding were 289,850 shares as of 2021-09-30.

Added: Immatics NV (IMTX)

Ikarian Capital, LLC added to a holding in Immatics NV by 292.22%. The purchase prices were between $11.58 and $15.46, with an estimated average price of $12.71. The stock is now traded at around $11.780000. The impact to a portfolio due to this purchase was 0.6%. The holding were 883,046 shares as of 2021-09-30.

Added: Compass Pathways PLC (CMPS)

Ikarian Capital, LLC added to a holding in Compass Pathways PLC by 169.45%. The purchase prices were between $29.03 and $38.62, with an estimated average price of $33.61. The stock is now traded at around $34.737500. The impact to a portfolio due to this purchase was 0.3%. The holding were 229,202 shares as of 2021-09-30.

Added: Gossamer Bio Inc (GOSS)

Ikarian Capital, LLC added to a holding in Gossamer Bio Inc by 28.95%. The purchase prices were between $7.25 and $13.23, with an estimated average price of $9.2. The stock is now traded at around $11.820000. The impact to a portfolio due to this purchase was 0.27%. The holding were 1,351,933 shares as of 2021-09-30.

Added: BioAtla Inc (BCAB)

Ikarian Capital, LLC added to a holding in BioAtla Inc by 179.93%. The purchase prices were between $29.44 and $43.74, with an estimated average price of $39.07. The stock is now traded at around $27.100000. The impact to a portfolio due to this purchase was 0.26%. The holding were 196,400 shares as of 2021-09-30.

Added: Corvus Pharmaceuticals Inc (CRVS)

Ikarian Capital, LLC added to a holding in Corvus Pharmaceuticals Inc by 657.55%. The purchase prices were between $1.89 and $8.53, with an estimated average price of $2.95. The stock is now traded at around $3.865000. The impact to a portfolio due to this purchase was 0.23%. The holding were 757,545 shares as of 2021-09-30.

Sold Out: Alector Inc (ALEC)

Ikarian Capital, LLC sold out a holding in Alector Inc. The sale prices were between $21.65 and $39.49, with an estimated average price of $28.1.

Sold Out: Annovis Bio Inc (ANVS)

Ikarian Capital, LLC sold out a holding in Annovis Bio Inc. The sale prices were between $30.95 and $120.97, with an estimated average price of $57.77.

Sold Out: Cullinan Oncology Inc (CGEM)

Ikarian Capital, LLC sold out a holding in Cullinan Oncology Inc. The sale prices were between $22.56 and $29.68, with an estimated average price of $26.76.

Sold Out: ChemoCentryx Inc (CCXI)

Ikarian Capital, LLC sold out a holding in ChemoCentryx Inc. The sale prices were between $13.18 and $19.83, with an estimated average price of $15.55.

Sold Out: Chardan Healthcare Acquisition 2 Corp (CHAQ.U)

Ikarian Capital, LLC sold out a holding in Chardan Healthcare Acquisition 2 Corp. The sale prices were between $9.46 and $11.11, with an estimated average price of $10.65.

Sold Out: I-MAB (IMAB)

Ikarian Capital, LLC sold out a holding in I-MAB. The sale prices were between $57.18 and $84.43, with an estimated average price of $72.45.



Here is the complete portfolio of Ikarian Capital, LLC. Also check out:

1. Ikarian Capital, LLC's Undervalued Stocks
2. Ikarian Capital, LLC's Top Growth Companies, and
3. Ikarian Capital, LLC's High Yield stocks
4. Stocks that Ikarian Capital, LLC keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus